Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/14/2019 10/15/2019 10/16/2019 10/17/2019 10/18/2019 Date
1684.2(c) 1655.6(c) 1636.2(c) 1651.8(c) 1646.2(c) Last
7 337 162 10 340 469 10 018 837 7 926 602 4 939 235 Volume
+0.55% -1.70% -1.17% +0.95% -0.34% Change
More quotes
Financials (GBP)
Sales 2019 32 761 M
EBIT 2019 8 857 M
Net income 2019 4 810 M
Debt 2019 23 845 M
Yield 2019 4,86%
Sales 2020 34 697 M
EBIT 2020 9 444 M
Net income 2020 5 051 M
Debt 2020 21 907 M
Yield 2020 4,86%
P/E ratio 2019 16,9x
P/E ratio 2020 16,2x
EV / Sales2019 3,21x
EV / Sales2020 2,98x
Capitalization 81 466 M
More Financials
Company
GlaxoSmithkline is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (56%): intended for respiratory diseases (40.1% of net sales), HIV infection (27.3%), immune system disorders (2.7%) ) and other (29,8%); - OTC and... 
Sector
Pharmaceuticals
Calendar
10/30 | 07:00amEarnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
10/18Sanofi pulls Zantac from U.S. and Canada after carcinogen found
RE
10/18Board of directors meeting of GlaxoSmithKline Consumer Healthcare Pakistan Li..
AQ
10/17TEVA PHARMACEUTICAL INDUSTRIES : UK arm recalls some batches of Ranitidine - Med..
RE
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
RE
10/15EUROPE MARKETS: European Stocks Surge To Best Level In 16 Months On Brexit Op..
DJ
10/15LONDON MARKETS: Pound Surges On Report Of Possible Draft Brexit Deal
DJ
10/12LONDON MARKETS: Brexit Hopes Sends British Pound To Highest Level Of Johnson ..
DJ
10/09UK accounting watchdog to get 80 more 'teeth'
RE
10/08GSK recalls popular heartburn drug Zantac globally after cancer scare
RE
10/08Glaxo Links Up with US Biotech to Target Solid Tumors with Cell Therapy
DJ
10/08GLAXOSMITHKLINE : Zantac - MHRA drug alert issued as GlaxoSmithKline recalls all..
AQ
10/07LONDON STOCK EXCHANGE : Trade hopes lift FTSE 100, SIG drags down mid-caps
RE
10/04Vectura, Sandoz win ruling on inhaler packaging case against GSK
RE
10/02GLAXOSMITHKLINE : GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients ..
BU
10/01Corporate Briefing Session of GlaxoSmithKline Consumer Healthcare Pakistan Li..
AQ
More news
News in other languages on GLAXOSMITHKLINE
10/16LONDON STOCK EXCHANGE : Londres suspendue aux négociations du Brexit
10/15Quelles entreprises tirent le STOXX 600 vers le haut ?
10/14LONDON STOCK EXCHANGE : La Bourse de Londres finit en baisse, les espoirs sur le..
10/14LONDON STOCK EXCHANGE : Londres en baisse, retour de la prudence sur le Brexit
10/01GSK : a présenté de nouvelles données sur l'asthme
More news
Analyst Recommendations on GLAXOSMITHKLINE
More recommendations
Sector news : Pharmaceuticals - NEC
02:48aJ&J Recalls Baby Powder For Asbestos -- WSJ
DJ
10/18More Money Demanded in Opioid Settlement Talks -- Update
DJ
10/18More Money Demanded in Opioid Settlement Talks
DJ
10/18JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 2nd Update
DJ
10/18Sanofi pulls Zantac from U.S. and Canada after carcinogen found
RE
More sector news : Pharmaceuticals - NEC
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 782,68  GBp
Last Close Price 1 646,20  GBp
Spread / Highest target 33,6%
Spread / Average Target 8,29%
Spread / Lowest Target -8,27%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE10.39%104 864
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.49%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.95%198 751